EP05.02-009 Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)

Abstract

For stage IIIA-N2 EGFR-mutant NSCLC, there have been several randomized controlled studies comparing various EGFR-TKI targeted therapy versus chemotherapy as neoadjuvant therapy. However, the role of third-generation EGFR-TKIs in neoadjuvant settings remains inconclusive. Aumolertinib (formerly almonertinib; HS-10296) is a novel, third-generation EGFR-TKI approved in China to treat EGFR-mutant NSCLC. The ANSWER study (NCT04455594) will assess the efficacy and safety of aumolertinib compared with erlotinib or platinum doublet chemotherapy (pemetrexed plus carboplatin or cisplatin) as neoadjuvant therapy in resectable patients with EGFR-mutant stage IIIA NSCLC.